

# Michael C Donohue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/491086/publications.pdf>

Version: 2024-02-01

80  
papers

9,462  
citations

87888

38  
h-index

64796

79  
g-index

94  
all docs

94  
docs citations

94  
times ranked

10726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitivity of the Preclinical Alzheimerâ€™s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimerâ€™s Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. <i>Journal of prevention of Alzheimer's disease, The</i> , 2022, 9, 255-261.	2.7	4
2	Basal Infusion versus Automated Boluses and a Delayed Start Timer for Continuous Sciatic Nerve Blocks after Ambulatory Foot and Ankle Surgery: A Randomized Clinical Trial. <i>Anesthesiology</i> , 2022, 136, 970-982.	2.5	3
3	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. <i>GeroScience</i> , 2022, 44, 1807-1823.	4.6	19
4	Time between milestone events in the Alzheimer's disease amyloid cascade. <i>NeuroImage</i> , 2021, 227, 117676.	4.2	20
5	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 293.	9.0	57
6	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	9.0	146
7	Serratus anterior plane versus paravertebral nerve blocks for postoperative analgesia after non-mastectomy breast surgery: a randomized controlled non-inferiority trial. <i>Regional Anesthesia and Pain Medicine</i> , 2021, 46, 773-778.	2.3	8
8	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12135.	3.7	11
9	The Computerized Cognitive Composite (C3) in A4, an Alzheimerâ€™s Disease Secondary Prevention Trial. <i>Journal of prevention of Alzheimer's disease, The</i> , 2021, 8, 1-9.	2.7	25
10	Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12118.	2.4	12
11	THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMERâ€™S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-5.	2.7	17
12	Neuroanatomical spread of amyloid $\beta^2$ and tau in Alzheimerâ€™s disease: implications for primary prevention. <i>Brain Communications</i> , 2020, 2, fcaa007.	3.3	69
13	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2020, 77, 735.	9.0	182
14	Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. <i>Alzheimer's and Dementia</i> , 2020, 16, 797-803.	0.8	4
15	The A4 study: Amyloid and cognition in 4432 cognitively unimpaired adults. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 776-785.	3.7	43
16	PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-6.	2.7	23
17	Predicting the course of Alzheimerâ€™s progression. <i>Brain Informatics</i> , 2019, 6, 6.	3.0	40
18	The relative efficiency of time-to-event progression and continuous measures of cognition in presymptomatic Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 308-318.	3.7	11

#	ARTICLE	IF	CITATIONS
19	Predicting diagnosis and cognition with $^{18}$ F- $\beta$ -galactosidase PET and structural MRI in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 570-580.	0.8	84
20	Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). <i>Journal of Alzheimer's Disease</i> , 2019, 70, 131-138.	2.6	18
21	Continuous Popliteal-Sciatic Blocks for Postoperative Analgesia: Traditional Proximal Catheter Insertion Superficial to the Paraneural Sheath Versus a New Distal Insertion Site Deep to the Paraneural Sheath. <i>Anesthesia and Analgesia</i> , 2019, 128, e104-e108.	2.2	4
22	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. <i>Alzheimer's and Dementia</i> , 2019, 15, 615-624.	0.8	5
23	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. <i>NeuroImage</i> , 2019, 186, 446-454.	4.2	16
24	Bayesian latent time joint mixed effect models for multicohort longitudinal data. <i>Statistical Methods in Medical Research</i> , 2019, 28, 835-845.	1.5	41
25	Disease progression models for dominantly-inherited Alzheimer's disease. <i>Brain</i> , 2018, 141, 1244-1246.	7.6	2
26	Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 657-668.	2.4	27
27	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. <i>Alzheimer's and Dementia</i> , 2018, 14, 1397-1405.	0.8	10
28	Sex, amyloid, and $\epsilon$ -APOE $\epsilon$ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1193-1203.	0.8	169
29	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 1077-1087.	0.8	83
30	Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. <i>Neurodegenerative Diseases</i> , 2018, 18, 173-190.	1.4	18
31	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid $\beta$ . <i>Alzheimer's and Dementia</i> , 2017, 13, 1004-1012.	0.8	139
32	Continuous Transversus Abdominis Plane Nerve Blocks: Does Varying Local Anesthetic Delivery Method "Automatic Repeated Bolus Versus Continuous Basal Infusion" Influence the Extent of Sensation to Cold?: A Randomized, Triple-Masked, Crossover Study in Volunteers. <i>Anesthesia and Analgesia</i> , 2017, 124, 1298-1303.	2.2	19
33	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2305.	7.4	311
34	Cross-validation of optimized composites for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 123-129.	3.7	18
35	Infection Rates of Electrical Leads Used for Percutaneous Neurostimulation of the Peripheral Nervous System. <i>Pain Practice</i> , 2017, 17, 753-762.	1.9	58
36	Accelerating rates of cognitive decline and imaging markers associated with $\beta$ -amyloid pathology. <i>Neurology</i> , 2016, 86, 1887-1896.	1.1	42

#	ARTICLE	IF	CITATIONS
37	Cognitive and functional changes associated with A $\beta$ pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016, 48, 172-181.	3.1	28
38	Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 747-755.	11.4	132
39	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 534-547.	3.7	32
40	Impact of CRFR1 Ablation on Amyloid- $\beta$ Production and Accumulation in a Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1175-1184.	2.6	32
41	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 239.	2.0	66
42	Independent information from cerebrospinal fluid amyloid- $\beta$ and florbetapir imaging in Alzheimer's disease. <i>Brain</i> , 2015, 138, 772-783.	7.6	200
43	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. <i>JAMA Neurology</i> , 2015, 72, 446.	9.0	142
44	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. <i>Alzheimer's and Dementia</i> , 2015, 11, 865-884.	0.8	181
45	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 734-739.	0.8	80
46	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. <i>Alzheimer's and Dementia</i> , 2015, 11, 823-831.	0.8	60
47	Clinical trial management of participant recruitment, enrollment, engagement, and retention in the SMART study using a Marketing and Information Technology (MARKIT) model. <i>Contemporary Clinical Trials</i> , 2015, 42, 185-195.	1.8	56
48	Predicting Reduction of Cerebrospinal Fluid $\beta$ -Amyloid 42 in Cognitively Healthy Controls. <i>JAMA Neurology</i> , 2015, 72, 554.	9.0	42
49	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2015, 11, 1069-1079.	0.8	22
50	The transitional association between $\beta$ -amyloid pathology and regional brain atrophy. <i>Alzheimer's and Dementia</i> , 2015, 11, 1171-1179.	0.8	37
51	Students at Risk for Being Reported for Cheating. <i>Journal of Academic Ethics</i> , 2015, 13, 217-228.	2.2	45
52	A randomized, triple-masked, active-controlled investigation of the relative effects of dose, concentration, and infusion rate for continuous popliteal-sciatic nerve blocks in volunteers. <i>British Journal of Anaesthesia</i> , 2015, 114, 121-129.	3.4	17
53	The A4 Study: Stopping AD Before Symptoms Begin?. <i>Science Translational Medicine</i> , 2014, 6, 228fs13.	12.4	588
54	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 534-543.	3.7	96

#	ARTICLE	IF	CITATIONS
55	The Preclinical Alzheimer Cognitive Composite. <i>JAMA Neurology</i> , 2014, 71, 961.	9.0	548
56	Emerging $\beta$ -Amyloid Pathology and Accelerated Cortical Atrophy. <i>JAMA Neurology</i> , 2014, 71, 725.	9.0	51
57	Association of brain amyloid- $\beta$ with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , 2014, 137, 1550-1561.	7.6	150
58	Design and implementation of a randomized controlled social and mobile weight loss trial for young adults (project SMART). <i>Contemporary Clinical Trials</i> , 2014, 37, 10-18.	1.8	91
59	Estimating long-term multivariate progression from short-term data. <i>Alzheimer's and Dementia</i> , 2014, 10, S400-10.	0.8	148
60	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	10.2	3,378
61	O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers. , 2013, 9, P521-P522.		2
62	Developing Dementia Prevention Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 356-362.	1.3	15
63	F3-04-01: The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, P425.	0.8	15
64	Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 360-364.	3.3	19
65	Continuous Femoral Nerve Blocks. <i>Anesthesiology</i> , 2012, 116, 665-672.	2.5	86
66	Continuous Femoral Nerve Blocks. <i>Anesthesia and Analgesia</i> , 2012, 115, 721-727.	2.2	26
67	The relative efficiency of time-to-threshold and rate of change in longitudinal data. <i>Contemporary Clinical Trials</i> , 2011, 32, 685-693.	1.8	25
68	Statistics and Clinical Data Analysis: A Reference Guide. , 2011, , 651-672.		0
69	Requiring an amyloid- $\beta$ biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. <i>Alzheimer's and Dementia</i> , 2011, 7, 245-246.	0.8	5
70	Continuous Femoral Nerve Blocks. <i>Anesthesiology</i> , 2011, 115, 774-781.	2.5	139
71	The Association Between Lower Extremity Continuous Peripheral Nerve Blocks and Patient Falls After Knee and Hip Arthroplasty. <i>Anesthesia and Analgesia</i> , 2010, 111, 1552-1554.	2.2	331
72	Pilot Study to Show the Feasibility of a Multicenter Trial of Home-based Assessment of People Over 75 Years Old. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 256-263.	1.3	16

#	ARTICLE	IF	CITATIONS
73	The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. <i>Alzheimer's and Dementia</i> , 2010, 6, 257-264.	0.8	102
74	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. <i>Alzheimer's and Dementia</i> , 2010, 6, 239-246.	0.8	402
75	Continuous Peripheral Nerve Blocks. <i>Anesthesiology</i> , 2010, 112, 347-354.	2.5	100
76	Applications of Neuroimaging to Disease-Modification Trials in Alzheimer's Disease. <i>Behavioural Neurology</i> , 2009, 21, 129-136.	2.1	17
77	Pediatricians' weight assessment and obesity management practices. <i>BMC Pediatrics</i> , 2009, 9, 19.	1.7	39
78	Parental Ability to Discriminate the Weight Status of Children: Results of a Survey. <i>Pediatrics</i> , 2007, 120, e112-e119.	2.1	99
79	Asynergistic Regression Based on Maximized Rank Correlation. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2007, 37, 92-105.	1.2	0
80	Proportional Hazards Mixed-Effects Models and Applications. <i>Chapman &amp; Hall/CRC Biostatistics Series</i> , 2007, , 297-322.	0.0	0